An optimized antibody-single-chain TRAIL fusion protein for cancer therapy

Fusion proteins combining oligomeric assemblies of a genetically obtained single-chain (sc) variant of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with antibodies directed against tumor-associated antigens represent a promising strategy to overcome the limited therapeutic activit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Siegemund, Martin, Seifert, Oliver, Zarani, Maria, Džinić, Tamara, De Leo, Valentino, Göttsch, Doris, Münkel, Sabine, Hutt, Meike, Pfizenmaier, Klaus, Kontermann, Roland E.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4968136/
https://ncbi.nlm.nih.gov/pubmed/27064440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1172163
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars